Co-Authors
This is a "connection" page, showing publications co-authored by Hossein Khalili and Hamid Rahmani.
Connection Strength
0.858
-
Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. Int Immunopharmacol. 2021 Jul; 96:107636.
Score: 0.235
-
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir. Daru. 2020 Dec; 28(2):625-634.
Score: 0.225
-
Interferon ß-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020 Nov; 88:106903.
Score: 0.225
-
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021 04 27; 325(16):1620-1630.
Score: 0.059
-
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thromb Haemost. 2022 Jan; 122(1):131-141.
Score: 0.059
-
A Randomized Clinical Trial of the Efficacy and Safety of Interferon ß-1a in Treatment of Severe COVID-19. Antimicrob Agents Chemother. 2020 08 20; 64(9).
Score: 0.056